
CJC-1295 No DAC + Ipamorelin
GHRH analogue + GH secretagogue blend
Pairs CJC-1295 (No DAC), a GHRH analogue, with Ipamorelin, a selective GH secretagogue — a gold-standard GH-stimulating combination for body composition support. Together they promote amplified, pulsatile GH release for recovery, body composition and sleep quality. Typical Course: A full course runs 12 weeks. It begins with a 2-week assessment phase at a lower dose (100mcg of each peptide, once daily before bed) so you can monitor sleep-quality changes, followed by a 10-week protocol at 100–300mcg of each peptide, dosed once or twice daily — typically morning and evening — for maximum GH pulse. Most customers notice initial effects around week 3, with results peaking around week 8. What to Expect: Improved sleep quality, faster recovery, leaner body composition and improved skin and hair quality. Key benefits include synergistic GH stimulation, twice-daily dosing flexibility, good tolerability and improved sleep quality. Considerations & Safety: This combination involves more frequent dosing, and water retention or carpal-tunnel-like tingling are possible; effects are generally less pronounced than exogenous GH. Common side effects include brief flushing (from Ipamorelin), water retention, headache and tingling in the extremities. Seek medical attention immediately if you experience significant swelling, signs of infection, severe headache, or chest pain.
10 mg (5+5)
99%+
900 AED
| Sequence | Available on request |
| Molecular Formula | Available on request |
| Molecular Weight | Available on request |
| CAS Number | 863288-34-0 / 170851-70-4 |
| Form | Reconstituted injection pen |
| Purity | ≥ 99%+ |
Related Compounds

CJC-1295 No DAC
Modified GRF (1-29)
GHRH analogue for pulsatile GH-release support.
850 AED

Ipamorelin
Selective growth-hormone secretagogue.
850 AED

Tesamorelin
GHRH analogue used for visceral-fat support.
750 AED

IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
Long-acting IGF-1 analogue for growth support.
1,150 AED